Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRH analogs for ovarian protection during gonadotoxic chemotherapy
2011-000207-40Phase 3Terminated
- Sponsor
- Fundación para la Investigación del Hospital Universitario Doctor Peset
- Start
- Jan 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of leuprolide in ovarian hypofunction (POI) and osteoporosis, sponsored by Fundación para la Investigación del Hospital Universitario Doctor Peset. Primary endpoint: Magnitude of protective effect on ovarian reserve. Started Jan 2012; status: terminated.
02
Drugs
leuprolide
03
Conditions
ovarian hypofunction (POI)osteoporosis
Beyond the preview
Go deeper on 2011-000207-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000207-40.